New C1&#8482 System Application Could Transform the Discovery of Causal Disease Mutations

Fluidigm's CyTOF® Mass Cytometry Instrument Unlocks Responses in Immune Cell Subsets

New System Provides Simple Workflow, Requires Minimal Amount of Sample Input and Hand

New Method   Decreases the Cost of Single-Cell Sequencing; Frees Up Resources to Analyze More Cells SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--In a paper published in  Nature Biotechnology  this week, UC San Francisco and Fluidigm Corporation (NASDAQ:FLDM) scientists have demonstrated that

Strong Q2 2014 organic revenue growth of 32% year-over-year

SOUTH SAN FRANCISCO, Calif., July 31, 2014 - Fluidigm Corporation (NASDAQ:FLDM) has begun accepting applications to an early access program for its upcoming imaging mass cytometry platform. Prototypes of the product are expected to begin shipping to early access partners by the end of this year.

SOUTH SAN FRANCISCO, Calif., July 23, 2014 — Fluidigm Corporation (NASDAQ:FLDM) will report its second quarter 2014 financial results on July 31, 2014, after close of market.   Gajus Worthington, Fluidigm president and chief executive officer, and Vikram Jog, chief financial officer, will host a

Study Demonstrates the Importance of Single-Cell Sequencing to Identify Rare Cell...

Program enables researchers to develop new single-cell applications on the C1&#8482 Single-Cell Auto Prep

Fluidigm Ships Flex six™ Integrated Fluidic Circuits to Genotyping and Gene Expression Customers   SOUTH SAN FRANCISCO, Calif., June 3, 2014 — Fluidigm Corporation (NASDAQ:FLDM) has begun shipping production volumes of its Flex Six™ integrated fluidic circuits (IFCs) to genotyping and gene